Tag:
OpRA III
Latest Headlines
Latest Headlines
Adolor inks $72M deal to in-license Lilly OBD drug
Adolor has plunked down $2 million upfront and committed to pay $70 million more in milestones for Eli Lilly's OpRA III, a clinical stage product being developed for opioid bowel dysfunction. Adolor
